SANIONA AB (PUBL)
Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical t… Read more
SANIONA AB (PUBL) (30S) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, SANIONA AB (PUBL) (30S) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
SANIONA AB (PUBL) - Net Assets Trend (None–None)
This chart illustrates how SANIONA AB (PUBL)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SANIONA AB (PUBL) (None–None)
The table below shows the annual net assets of SANIONA AB (PUBL) from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to SANIONA AB (PUBL)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
SANIONA AB (PUBL) Competitors by Market Cap
The table below lists competitors of SANIONA AB (PUBL) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tianjin Motimo Membrane Tech
SHE:300334
|
$183.70 Million |
|
Selvas Ai Inc.
KQ:108860
|
$183.73 Million |
|
Chemplast Sanmar Limited
NSE:CHEMPLASTS
|
$183.76 Million |
|
Indraprastha Medical Corporation Limited
NSE:INDRAMEDCO
|
$183.78 Million |
|
Hefei Department Store Group Co Ltd
SHE:000417
|
$183.52 Million |
|
Monogram Orthopaedics Inc. Common Stock
NASDAQ:MGRM
|
$183.49 Million |
|
Bonava AB (publ)
ST:BONAV-B
|
$183.49 Million |
|
Mayne Pharma Group Limited
PINK:MAYNF
|
$183.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SANIONA AB (PUBL)'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares SANIONA AB (PUBL)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently SANIONA AB (PUBL) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares SANIONA AB (PUBL)'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SANIONA AB (PUBL) (30S) | €- | N/A | N/A | $183.59 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |